Earnings Feed
Start Free
MapLight Therapeutics, Inc.·4

Jul 20, 6:00 AM ET

GILLIS JONATHAN 4

Research Summary

AI-generated summary

Updated

MapLight (MPLT) CAO/Interim CFO Jonathan Gillis Sells Shares

What Happened
Jonathan Gillis, MapLight Therapeutics' Chief Accounting Officer and Interim CFO, disposed of 36,979 shares in a series of open‑market sales between July 15–17, 2026, generating total gross proceeds of approximately $1,372,667. Individual transactions ranged from ~600 to 16,969 shares at weighted average prices between $36.13 and $38.17 per share. Several of the sales were routine—some were mandated to cover tax withholding on vested restricted stock units and at least one sale was executed under a pre‑existing 10b5‑1 trading plan.

Key Details

  • Filing date: July 20, 2026. Reported transaction dates: July 15–17, 2026. (Timeliness not indicated in the provided data.)
  • Aggregate sold: 36,979 shares for approx. $1,372,667 total.
  • Transaction breakdown (date — shares — weighted avg price — proceeds — footnote):
    • 2026-07-15 — 5,356 sh @ $36.13 — $193,512 (F1/F2)
    • 2026-07-15 — 4,699 sh @ $36.94 — $173,581 (F4)
    • 2026-07-16 — 6,979 sh @ $36.66 — $255,850 (F3)
    • 2026-07-16 — 1,476 sh @ $37.44 — $55,261 (F5)
    • 2026-07-17 — 600 sh @ $36.51 — $21,906 (F7)
    • 2026-07-17 — 16,969 sh @ $37.61 — $638,204 (F8; includes a 10b5‑1 plan reference F6)
    • 2026-07-17 — 900 sh @ $38.17 — $34,353 (F9)
  • Shares owned after the transactions: not reported in the provided filing data.
  • Notable footnotes:
    • F1: Certain sales were "sell‑to‑cover" to satisfy statutory tax withholding on vested RSUs (not discretionary).
    • F6: At least one transaction was made pursuant to a Rule 10b5‑1 trading plan adopted Dec 26, 2025.
    • F2–F5, F7–F9: Prices reported are weighted averages; each footnote lists the price ranges for multiple executions and the filer offers to provide per‑trade details on request.

Context
These transactions are sales (not purchases). Sell‑to‑cover transactions are routine and required for tax withholding on RSU vesting and do not necessarily indicate a change in sentiment. A 10b5‑1 plan sale means that at least some transactions were pre‑planned. For retail investors, purchases typically carry more informational weight than routine disposals; this filing documents multiple orderly sales rather than an acquisition or option exercise.